drugset
drugset / Trial / NCT00112463

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

NCT00112463 ↗

Phase 2 Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2005-01-07
Primary completion
2008-10-23
Completion
2008-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide 13 mg/m2 Intravenous

Indications

Ewing sarcoma/peripheral primitive neuroectodermal tumor adult epithelioid sarcoma adult extraskeletal osteosarcoma adult fibrosarcoma adult liposarcoma adult malignant hemangiopericytoma adult malignant mesenchymoma alveolar soft part sarcoma angiosarcoma chondrosarcoma gastrointestinal stromal tumor leiomyosarcoma neurofibrosarcoma rhabdomyosarcoma synovial sarcoma undifferentiated pleomorphic sarcoma